Ultragenyx Pharmaceutical Inc. - Common Stock (RARE)
26.31
-1.10 (-4.01%)
NASDAQ · Last Trade: Jul 18th, 8:23 PM EDT
Detailed Quote
Previous Close
27.41
Open
27.41
Bid
26.15
Ask
26.60
Day's Range
26.00 - 27.50
52 Week Range
26.00 - 60.37
Volume
3,905,839
Market Cap
1.86B
PE Ratio (TTM)
-4.482
EPS (TTM)
-5.9
Dividend & Yield
N/A (N/A)
1 Month Average Volume
2,475,089
Chart
About Ultragenyx Pharmaceutical Inc. - Common Stock (RARE)
Ultragenyx Pharmaceutical is a biopharmaceutical company focused on developing and commercializing innovative therapies for the treatment of rare genetic disorders. The company specializes in creating novel treatments targeting serious diseases caused by genetic mutations, particularly those that affect critical metabolic pathways. With a strong emphasis on research and development, Ultragenyx strives to bring hope and improved quality of life to patients living with rare conditions by harnessing cutting-edge science and technology to address unmet medical needs. Read More
NOVATO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultra-rare diseases, today reported the grant of 45,292 restricted stock units of the company’s common stock to 29 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company’s board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of July 16, 2025, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or “the Company”) (NASDAQ: RARE) for violations of the securities laws.
NEW YORK, July 18, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
Stay up-to-date with the latest market trends in the middle of the day on Thursday. Explore the top gainers and losers during today's session in our detailed report.
Let's have a look at what is happening on the US markets after the closing bell on Wednesday. Below you can find the top gainers and losers in today's after hours session.
